Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Ligand purchases Marathon Biopharmaceuticals' assets

Feb. 15, 1999

PSP94 suppresses prostate cancer growth in mouse model

Feb. 12, 1999

Enrollment completed in Maxim's malginant melanoma phase III trial

Feb. 9, 1999

Ligand receives FDA approval for Ontak as CTCL treatment

Feb. 8, 1999

ImmunoGen and SB enter agreement for colorectal cancer treatment

Feb. 4, 1999

Phase I clinical trial of novel cervical dysplasia Rx from StressGen

Feb. 3, 1999

SWOG phase II study of safety and efficacy of rhIL-4 in malignant melanoma

Jan. 25, 1999

Polish authorities allow phase II testing of Multikine

Jan. 15, 1999

Health Canada approves new indication for Proleukin

Jan. 12, 1999

Proleukin receives orphan drug status for two new indications

Jan. 7, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld
Hematopoietic stem cell research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Korsana boosts Alzheimer’s work with reverse merger, $380M financing
BioWorld Science
Just over a month after emerging from stealth and disclosing a $150 million series A, Korsana Biosciences Inc. is making the leap to the public market via a...